







an Open Access Journal by MDPI

Current Clinical Studies of Pancreatic Ductal Adenocarcinoma

Guest Editor:

Dr. Govindarajan Narayanan

- 1. Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33176, USA
- 2. Miami Cardiac and Vascular, Baptist Health South Florida, Miami, FL 33176, USA
- 3. Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA

Deadline for manuscript submissions:

20 April 2025

Message from the Guest Editor

We would like to annnounce the launch of a Special Issue on 'Current Clinical Studies of Pancreatic Ductal Adenocarcinoma' which will take the form of a multidisciplinary project, incoporating research on medical oncology, current trends in neoadjuvant and adjuvant chemotherapy for pancreatic cancer, and surgical managements such as open and minimally invasive techniques. This Special Issue will also highlight studies on the locoregional treatment space including advances in SBRT and MR-guided Linac along with irreversible electroporation (IRE) using an open surgical approach and a percutaneous approach. Additionally, bench research analyzing the role of local treatment in enhancing immune response and/or the impact of local treatment on the stromal tissue of pancreatic cancer, which improves the uptake of immunotherapy, will also be incorporated.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us